Document is current
Any future updates will be listed below
-
Authors
Smythies, James A
Sun, Min
Masson, Norma
Salama, Rafik
Simpson, Peter D
Murray, Elizabeth
Neumann, Viviana
Cockman, Matthew E https://orcid.org/0000-0002-3310-4821
Choudhry, Hani
Ratcliffe, Peter J https://orcid.org/0000-0002-2853-806X
Mole, David R https://orcid.org/0000-0002-0984-300X
-
Funding
Funding for this research was provided by:
Cancer Research UK (A416016)
Cancer Research UK (FC001501)
DH | National Institute for Health Research (NIHR‐RP‐2016‐06‐004)
The Deanship of Scientific Research, KAU, Ministry of High Education for Saudi Arabia
Wellcome Trust (088182/Z/09/Z)
Wellcome Trust (078333/Z/05/Z)
Wellcome Trust (WT091857MA)
Wellcome Trust (203141/Z/16/Z)
Wellcome Trust (FC001501)
Ludwig Institute for Cancer Research
UK Medical Research Council (FC001501)
- License Information
-
More Information
Article History
Received: 10 May 2018
Revised: 9 October 2018
Accepted: 17 October 2018
First Online: 14 November 2018
Conflict of interest
: Peter J Ratcliffe is a scientific co‐founder of ReOx Ltd., a company, which is developing inhibitors of the HIF hydroxylase enzymes. The other authors declare that they have no conflict of interest.
